GlassScriptPhysician profile
Julia Klusty
NPI 1922518901
$2,750.76
in general payments reported to CMS, 2019-2025
33 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $517 · 2023: $717 · 2024: $966 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.46 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $313.21 | 2023-2024 | Carvykti, Tecvayli, Darzalex |
| E.R. Squibb & Sons, L.L.C. | $269.03 | 2021-2025 | Opdivo, Opdualag, Pomalyst |
| Incyte Corporation | $263.87 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Janssen Pharmaceuticals, INC | $224.23 | 2021-2022 | |
| Abbvie INC. | $196.53 | 2021-2025 | |
| Glaxosmithkline, LLC. | $160.67 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Pfizer INC. | $155.30 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $143.10 | 2023-2024 | Lynparza, Imfinzi, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $123.28 | 2022 | |
| Alexion Pharmaceuticals, INC. | $83.83 | 2023-2024 | Ultomiris |
| Eisai INC. | $74.80 | 2022-2024 | |
| Amgen INC. | $66.68 | 2022-2023 | Lumakras, Xgeva, Vectibix |
| Beigene USA, INC. | $61.74 | 2023-2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $57.41 | 2024-2025 | |
| Daiichi Sankyo INC. | $56.38 | 2022-2024 | Enhertu |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $39.37 | 2025 | Orserdu |
| Genentech USA, INC. | $38.04 | 2024 | Phesgo, Columvi, Polivy |
| Ucb, INC. | $35.30 | 2021 | |
| Merck Sharp & Dohme LLC | $33.92 | 2022-2024 | Welireg, Keytruda |
| Emd Serono, INC. | $32.06 | 2024 | |
| Lilly USA, LLC | $31.36 | 2023-2024 | Jaypirca, Verzenio |
| Novartis Pharmaceuticals Corporation | $28.22 | 2023 | |
| Immunogen, INC. | $27.83 | 2023 | Elahere |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.10 | 2022 | |
| Tersera Therapeutics LLC | $25.74 | 2023 | Xermelo |
| Seagen INC. | $25.14 | 2023 | Padcev |
| Tolmar, INC. | $24.98 | 2023 | |
| Exelixis INC. | $23.25 | 2022 | |
| Blueprint Medicines Corporation | $23.01 | 2024 | Ayvakit |
| Array Biopharma INC | $22.72 | 2023 | Braftovi, Lorbrena, Paxlovid |
| Astellas Pharma US INC | $22.31 | 2023 | Xtandi |
| Regeneron Healthcare Solutions, INC. | $21.71 | 2023 | Libtayo |
| Tempus Ai, INC | $19.64 | 2025 | Xt Cdx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Klusty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.